Immediate as well as early revascularisation may be beneficial in patients with acute coronary syndromes (ACS) without ST elevation, but has traditionally employed as an 'ischemia-guided' strategy. A number of randomised trials (including more than 10,000 patients) and observational studies have compared routine invasive versus selective invasive treatment in patients with an acute coronary syndrome without ST elevation. Most 
Introduction
Prognosis of patients with stable angina is in general very good, with an incidence of death or non-fatal myocardial infarction not exceeding 2% per ___________________________________________________________________ 14 year [1] . In contrast, patients with an acute coronary syndrome (ACS) without ST elevation (NSTE-ACS) have a much worse prognosis, as 10-15% experience death or non-fatal myocardial infarction within one year after admission [2] . According to the European and American treatment guidelines, and based on a large number of randomised trials, medical therapy of NSTE-ACS patients should preferably include heparin, antiplatelet agents and anti-ischemic agents [3] . Coronary revascularisation by either percutaneous coronary intervention (PCI) or coronary bypass surgery (CABG) is recommended in patients with recurrent ischemia, as well as in those who are otherwise at increased risk. In clinical practice, however, an important limiting factor to offer coronary revascularisation is its availability [4] . Patients presenting to hospitals without facilities for coronary revascularisation are much less likely to receive such treatment than those who present to hospitals with more extensive equipment. A number of registries and randomised trials describe potential benefits of (early) revascularisation in NSTE-ACS patients. We aimed to review these data.
Randomised trials
Between 1994 and 2002 eight clinical trials were undertaken, which randomised approximately 9000 NSTE-ACS patients to an early invasive or conservative treatment strategy [5] [6] [7] [8] [9] [10] [11] . Recently, results of an additional trial (ICTUS) were published [12] . In most trials, patients randomised to invasive treatment underwent cardiac catheterisation during the first days after hospital admission (in the majority of patients cardiac catheterisation Chapter 2 ___________________________________________________________________ 15 was performed within 72 h), and, if necessary, revascularisation as soon as possible thereafter. Treatment decisions in patients randomised to the conservative treatment strategy were left to the discretion of the physician, and were mainly based on symptoms. All trials together, early invasive treatment was not associated with a mortality reduction after one-year follow-up (table 1; figure 1 left panel), although in a recently published meta-analysis it was shown that after hospital discharge the invasive approach is associated with mortality reduction after long-term follow-up [13] . Early invasive treatment was associated with a borderline statistically significant 12% relative reduction -and a 1.1% absolute reduction -in the composite endpoint of death or non-fatal myocardial infarction during longterm follow-up compared with conservative treatment (8.7% versus 9.8% events; odds ratio 0.88 and 95% CI 0.77-1.0). However, there was evidence of a differential treatment effect between the separate trials. Revascularisation for NSTE-ACS ___________________________________________________________________ odds ratio 3.7 and 95% CI 1.0-13.6). A meta-analysis of the five recent trials revealed a 28% relative reduction -and a 2.5% absolute reductionin the composite endpoint of death or non-fatal myocardial infarction by the early invasive strategy (7.0% versus 9.5% events; odds ratio 0.72 and 95%
16
CI 0.60-0.86).
In ICTUS, a total of 1201 NSTE-ACS patients who had a cTnT concentration >0.03 μg/L at presentation, were randomly assigned to a treatment strategy that aimed at coronary angiography and subsequent revascularisation within 24-48 hrs (early invasive approach) or to a treatment strategy in which coronary angiography (and revascularisation) was only performed in cases of refractory angina or ischemia on predischarge exercise testing (selective invasive approach). In both treatment arms abciximab was given whenever a PCI was performed, whereas coronary stents were used liberally. Within one year after randomisation, coronary revascularisation was performed in 73% of Revascularisation for NSTE-ACS ___________________________________________________________________ 18 patients allocated to early invasive treatment versus 47% in those allocated to selective invasive treatment, whereas timing of revascularisation was within 30 days in almost all patients who had revascularisation. The early invasive approach was associated with an increased incidence of non-fatal myocardial infarction during one-year follow-up compared to the selective invasive approach (15% versus 10%; odds ratio 1.5 and 95% CI 1.1 -2.0), but most events were related to the revascularisation. Patients allocated to the invasive approach had a lower incidence of rehospitalisation for ACS within one year (7.4% and 10.9%; odds ratio 0.68, 95% CI 0.47-0.98).There was no difference in all-cause mortality after one year between the separated approaches (2.5% versus 2.5%; odds ratio 0.99 and 95% CI 0.49-2.00). Compared to the other randomised trials, patients allocated to conservative treatment had a high frequency of cross-over to (early) revascularisation (47%) and a low one-year mortality (2.5% in ICTUS vs.
4.4% in the other trials).
Apart from potential effects on mortality and recurrent MI, in the randomised trials it was shown that early revascularisation may particularly reduce anginal complaints and rehospitalisation [13] . Also in ICTUS, the incidence of rehospitalisation for anginal complaints was significantly lower in those allocated to the early invasive strategy.
Randomised controlled trials are the cornerstone of evidence based medicine. Still, clinical trials comparing invasive versus medical approach in NSTEMI should be interpreted with caution. Importantly, in these trials, many patients allocated to conservative treatment crossed-over to invasive treatment, whereas many patients allocated to invasive treatment did not undergo such therapy. Furthermore, patients included in these trials consist a selected patient group, with differences to patients seen in daily clinical practice. Also, these trials cannot be blinded to treatment allocation. These factors may have caused bias, and particularly cross-over in the conservative group may have contributed to an underestimation of the benefits with an invasive approach in NSTE-ACS.
Observational studies
Apart from the randomised trials, there are several observational studies, including registries, regarding the potential benefit of revascularisation in patients with ACS without ST elevation [14] [15] [16] [17] [18] [19] . In the OASIS registry, evaluating approximately 8000 patients with suspected NSTE-ACS from 6
countries, a reduction in refractory ischemia and need for hospitalisation was observed after revascularisation, but not a decrease of mortality [16] .
Analyses of data from patients included in GUSTO IV-ACS provided evidence that coronary revascularisation within 30 days after admission was associated with a favourable one-year survival, with one-year mortality 2.3% in the invasive group vs 5.6% in the conservative group [17] . This beneficial effect of revascularisation was also observed after adjusting for several baseline characteristics and a propensity score: patients with revascularisation had a relative risk of one-year mortality of 0.53 (95% CI 0.37-0.77) compared to patients without revascularisation. Moreover, in this analysis, survival benefit after revascularisation, independent of early risk stratification, was consistently shown in every subgroup studied. 
Revascularisation in practice
Recent European and American guidelines for clinical practice advise an invasive strategy in patients with ACS and failed medical therapy as well in high risk patients [3, 20] . This is in agreement with observations from FRISC II and TACTICS-TIMI 18 demonstrating that the absolute reduction of death or subsequent myocardial infarction is highest in high-risk groups. Failure of Chapter 2 ___________________________________________________________________ 21 medical therapy include ST segment depression >0.1 mV, accelerated angina in the prior 2 months, nitrate use in the prior week before admission and elevated troponin [21] . Whether other diagnostic tools, such as (contrast) echocardiography may be helpful in selecting patients for an early invasive approach should be assessed [22, 23] . Finally, although a number of studies suggest benefits of revascularisation, data from registries showed that in daily clinical practice an early invasive management strategy is commonly denied in many high-risk patients with NST-ACS [18, [24] [25] .
Timing of revascularisation
The hazard of an unfavourable event in patients with NST-ACS is highest within the first 48 hours after admission [26] . Nevertheless, the appropriate timing of coronary angiography and revascularisation remains controversial. In an early invasive approach, the risk of peri-procedural complications may be increased [27] . Therefore, a period of 'cooling off', in which patients are medically stabilised, has been recommended. This allows partial resolution of the initially strong inflammatory response with liberation of cytokines [28] , increased generation of free radicals [29] , and enhanced activity of the coagulation system [30] . On the other hand, early angiography and subsequent revascularisation may prevent myocardial infarction or death in a high risk period, particularly with the use of stents and GP IIb/IIIa inhibitors. In PURSUIT, early PCI (within 24 h) in patients receiving a GP IIb/IIIa inhibitor had the lowest event rate after 30 days [31] .
In TACTICS TIMI 18, there was no mortality difference between patients Revascularisation for NSTE-ACS ___________________________________________________________________ 22 with revascularisation within 48 hours after randomisation, and those with revascularisation after 48 hours [32] . In GUSTO IV-ACS, an increased mortality was found in patients with early CABG [17] . Possibly, when indicated, PCI should be performed, as soon as possible after admission for ACS while CABG should be deferred. However, until now, there are only few randomised data available, comparing an early with a later invasive approach, showing conflicting results [33, 34] .
Angioplasty or surgery
In the randomised trials of invasive versus conservative management in ACS, there are different findings with regard to mortality after CABG. In FRISC II the in-hospital and 30-day mortality after CABG in the invasive group was respectively 1.2% and 2.1%. Similar low rates were observed in TACTICS TIMI 18, and outcome was comparable between patients undergoing CABG and PCI. In VANQWISH, however, there was a very high mortality in the CABG group. In recent randomised trials comparing stented angioplasty and bypass surgery, which included patients with non-STEMI, the incidence of death or myocardial infarction during follow-up of 2 years were similar between the two groups [35, 36] . The less favourable outcome after CABG in GUSTO IV-ACS was most likely related to the selection of patients with more extensive disease to undergo surgery. Data of randomised studies with drug-eluting stents are not yet available.
Whether complete revascularisation may reduce mortality compared to revascularisation of the culprit lesion is unknown. A small study showed no mortality difference, but a trend to fewer readmissions for unstable angina and less long-term antianginal medication [37] .
GP IIb/IIIa inhibitors
A number of previous studies have demonstrated beneficial effects of GP IIb/IIIa inhibitors in patients with ACS without ST elevation, in particular in patients undergoing PCI [38] [39] [40] [41] . In the guidelines of management of patients with non-STEMI, use of GP IIb/IIIa inhibitors are recommended, in addition to standard treatment (aspirin and unfractionated heparin or lowmolecular-weight heparins) for patients with high-risk features such as elevated troponin, ST-segment changes, or recurrent ischaemia [3, 42] . GP IIb/IIIa inhibitors are particularly effective in patients with NSTE-ACS when early PCI is performed [31] . GUSTO IV-ACS did not show beneficial effects of abciximab [17] . However, in this trial, coronary angiography was discouraged within 60 h after randomisation unless the patient had recurrent or continuing ischemia at rest associated with ischemic ST-T changes that were unresponsive to intensive medical therapy. Indeed, only 128 patients (1.6%) had PCI during study drug infusion.
In summary, in patients with non-ST-segment elevation ACS and early invasive management, optimal pharmacological therapy should be supported, including GP IIb/IIIa antagonists [43] . However, in women and troponin-negative patients data are less clear and enhanced risk stratification is needed in these subgroups [44] . Furthermore, all previous large trials on GP IIb/IIIa inhibitors during PCI for non-ST ACS have been performed without routine use of clopidogrel. A relative small study was Revascularisation for NSTE-ACS ___________________________________________________________________ 24 recently published, and suggested no benefit of routine GP IIb/IIIa inhibitors compared to provisional use in patients with non-ST ACS treated with aspirin, heparin and clopidogrel [45] .
Sub-groups of patients
There are several patient characteristics that should be considered in patient selection for revascularisation. Although increasing age is an important risk factor for adverse outcome among patients with acute coronary syndromes, elderly patients are more often managed conservatively. A sub-analysis of patients of the TACTICS-TIMI 18 trial showed that, despite an increased risk for major bleeding in patients older than 75 years of age, a routine early invasive strategy can significantly improve ischemic outcomes in elderly patients with unstable angina and non-ST segment elevation MI [46] . These data have been confirmed in other studies [47, 48] .
In patients admitted with NSTE-ACS, females are often older and have more often diabetes mellitus or hypertension [49] [50] [51] . It has been suggested that GP IIb/IIIa inhibitors are not beneficial in females with unstable angina [52] and that invasive treatment is less effective in females compared to males [53, 54] . This was, however, not confirmed by other studies [55] . Also data from GUSTO IV-ACS did not show significant differences between males and females regarding mortality reduction of revascularisation [17] .
In most studies, diabetic patients admitted with a non-ST elevation ACS are older and more likely to be female than non-diabetic patients. They have Chapter 2 ___________________________________________________________________ 25 more previous cardiovascular events, including MI, congestive heart failure, stroke, and revascularisation procedures [56] . Furthermore, diabetes is an independent predictor of mortality after a non-ST elevation ACS [56] [57] [58] .
Coronary revascularisation in patients with diabetes and non-ST elevation ACS may be, however, as effective as in patients without diabetes [59] .
Conclusions
Although the results observed in randomised trials are less clear than observational studies, we believe that angiography and revascularisation should be strongly considered during the initial hospitalisation in high-risk patients with NSTE-ACS and in case of failure of medical therapy in suppressing ischemia. The optimal timing of angiography and subsequent revascularisation if appropriate remains uncertain, but possibly PCI should be performed as soon as possible after admission for ACS, while CABG should be deferred. We did not review data on benefits of revascularisation apart from survival or recurrent MI, but patients have probably less complaints during follow-up after revascularisation, as was shown in RITA 3.
